Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
04/25/2024 | Press release | Distributed by Public on 04/25/2024 05:15
Please select the service you want to use:
Smartlinks | MKD Taurus d.o.o. Banja Luka | Finance | Security Markets | Security Markets | Company News | Private Companies | Consumer Lending Companies
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact